Pensilina

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pensilina

Pensilina: Definition and Pharmacological Class

Pensilina is an injectable medicine containing the active ingredient Benzylpenicillin, also known as Penicillin G. This medication is classified as a beta-lactam antibiotic, serving as an anti-infective agent. The primary function of this medicine relies on Benzylpenicillin, which is utilized for its activity against various susceptible organisms.

Benzylpenicillin is considered an essential medicine for the treatment of various bacterial infections. Unlike broad-spectrum antibiotics, Benzylpenicillin is a narrow-spectrum agent, which allows for targeted application against specific, susceptible bacteria.


Composition, Origin, and Supply Form

The medicine is a single-ingredient product derived from Penicillium fungi, characterizing it as an antibiotic of biosynthetic origin. Pensilina is supplied as a sterile powder for injection solution that requires reconstitution with an appropriate aqueous solvent before administration via the parenteral route.

This parenteral form is used in clinical situations, such as severe acute infections, where rapid systemic concentrations are required. This method of administration allows the active compound to bypass the digestive system, facilitating availability in the bloodstream to reach the site of infection.

What side effects are possible with Pensilina?

Possible Side Effects and Safety Information

The safety profile of Pensilina (Benzylpenicillin) is structured by official regulatory classifications, detailing possible adverse effects by frequency and the organ systems involved. The most prominent safety concern documented is hypersensitivity (allergic reactions), which is commonly reported and includes reactions such as skin rash and fever.

Less frequently, serious adverse reactions have been documented, including anaphylactic reactions which are classified as rare but are explicitly highlighted in official labeling. Other serious reactions include specific Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome, and Convulsions related to Central Nervous System (CNS) toxicity.

System-Organ Class (SOC) Documented Adverse Reactions
Immune System Hypersensitivity, Anaphylaxis, Angioedema
Nervous System Convulsions, Encephalopathy (primarily high doses/renal impairment)
Blood and Lymphatic Neutropenia, Thrombocytopenia (associated with prolonged high doses)
Gastrointestinal Diarrhea, Pseudomembranous Colitis

Safety notes also address specific administration contexts. In the presence of renal impairment, the risk of CNS toxicity is specifically elevated due to reduced drug clearance. Furthermore, treating spirochetal infections (e.g., syphilis) can lead to the Very Common Jarisch–Herxheimer reaction. Pseudomembranous colitis is a documented risk that may occur up to months after the cessation of therapy. The label also contains restrictions, contraindicating use in individuals with a known severe allergy to cephalosporins due to the risk of cross-sensitivity.

Overdose and Emergency Response

Overdose and when to seek help

Documented Manifestations and Severe Outcomes

Pensilina overdose is formally documented to present with serious Central Nervous System (CNS) toxicity, with primary clinical signs including convulsive seizures and neuromuscular hyperirritability. In extreme cases of high systemic exposure, outcomes can escalate to Coma or fatal electrolyte disturbances (hypernatraemia). Due to the sodium content in high intravenous doses, there is also a documented risk of congestive heart failure in susceptible patients. The most serious outcomes are classified by specific end-organ effects, such as CNS failure or severe renal tubular damage.


Emergency Response and Population Constraints

If an overdose is suspected, immediate medical attention must be sought. Official regulatory documents state clearly that individuals should contact the local poison control center or emergency room immediately. Management is restricted to symptomatic and supportive treatment, as no specific antidote is known. The official profile notes a critical population constraint: patients with impaired renal function face a significantly higher risk for neurotoxic effects because the drug accumulates easily. Haemodialysis is listed as a procedural step that may be utilized for enhanced drug elimination in severe cases.

Therapeutic Uses of Pensilina

What Pensilina Treats: Main Uses and Benefits

Pensilina (Benzylpenicillin) is a focused anti-infective agent generally used to treat a spectrum of serious bacterial infections that cause severe, acute symptomatic distress. Its therapeutic role is applied to help eliminate highly susceptible bacteria, providing the benefit of managing life-threatening systemic and deep-seated tissue infections.


This medication is commonly used in clinical settings involving acute and extensive bacterial activity, such as septicaemia, bacterial meningitis, and endocarditis. It also serves as a relevant therapeutic option for specific systemic diseases like syphilis and is considered relevant as a preventative measure (prophylaxis) to manage the potential recurrence of strep diseases, which may assist in reducing the risk of developing rheumatic heart disease.

“This type of therapy is relevant when systemic bacteria threaten functional stability, and supportive symptom management is appropriate.”

A primary therapeutic benefit is that it helps address critical symptoms related to systemic imbalance, such as dangerously high fever and severe chills, while supporting managing the progression of the infection. It contributes to improved comfort and may assist with maintaining functional stability during periods of heightened distress.

Quick Fact: Relief for Acute Systemic Symptoms
Pensilina is applied in addressing symptom clusters like high fever and profound fatigue associated with conditions marked by temporary physiological imbalance. It supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.

Regulatory References

  1. Official UK Medicines Compendium (eMC)

Eligibility and Restrictions for Use

Eligibility for Pensilina: Official Regulatory Profile

Pensilina (Benzylpenicillin) is contraindicated in patients with a known history of hypersensitivity or allergic reaction to any penicillin, or to the specific excipients in the injection formulation. Use is also not recommended for those with a history of severe, immediate hypersensitivity reactions to other beta-lactam antibiotics, such as cephalosporins, due to the regulatory caution regarding cross-allergenicity.

Eligibility Scope Official Regulatory Statement
Conditional Restriction Eligibility is restricted for patients with impaired renal function, who require a mandatory dose reduction or extended dosing interval to mitigate the risk of neurotoxicity.
Age-Related Rules The medicine is approved for Adults and Children. Use in Neonates and Premature Babies is conditional and requires an extended dosing interval due to their reduced renal clearance. Dose reduction may be necessary for Older Adults.
Special Caution Caution is required in patients with epilepsy, severe heart conditions (due to the sodium content), and a history of significant allergies or asthma.
Reproductive Status Use is not contraindicated during pregnancy. It is considered acceptable while breastfeeding, with caution advised regarding the small amount excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Pensilina is defined by a primary risk of hyperkalemia when combined with specific classes of medicines that affect potassium levels or fluid balance.

Documented Interaction Categories

Product Category Interaction Mechanism / Result Classification
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Increased risk or severity of hyperkalemia. Significant Risk (Pharmacodynamic)
ACE Inhibitors (e.g., Captopril, Enalapril) Increased risk or severity of hyperkalemia. Significant Risk (Pharmacodynamic)
Potassium-Sparing Diuretics (e.g., Amiloride) Increased risk or severity of hyperkalemia. Significant Risk (Pharmacodynamic)
Antacids and Iron Supplements Potential for affected absorption of Pensilina. Caution Advised (Pharmacokinetic)
Hormonal Contraceptives Potential interaction, though the level of supporting scientific evidence is noted as scarce in some documents. Potential Interaction

Official Interaction Statements

  • Concomitant use with agents such as NSAIDs, ACE Inhibitors, and specific potassium-affecting cardiovascular medications may lead to an increased risk or severity of hyperkalemia (abnormally high potassium levels).
  • The drug's absorption may be reduced or altered when co-administered with certain antacids and iron-containing products.
  • A potential drug interaction with hormonal contraceptives has been noted in structured reviews, although regulatory sources indicate that the scientific evidence supporting a significant clinical effect remains limited.

The overall interaction structure, as defined in regulatory documents, centers on the need to monitor and manage the potential for severe hyperkalemia when combining Pensilina with other high-risk medications. This pharmacodynamic effect represents the most clinically significant area of documented concern.

Mechanism of Action

Pensilina (Benzylpenicillin) is a bactericidal agent whose mechanism of action is selective, targeting the fundamental structural components of the bacterial cell. Its action targets structural and enzymatic processes unique to the bacterial cell.

Disrupting Bacterial Cell Wall Assembly

The drug's primary action is the irreversible inhibition of key bacterial enzymes called Penicillin-Binding Proteins (PBPs), specifically DD-transpeptidases. These enzymes are essential for cross-linking the structural peptidoglycan strands that provide the cell wall's rigidity. By covalently binding to the active site of the PBP, Pensilina halts this critical assembly process.


Inducing Structural Lysis

The failure of the cell wall to assemble properly leads to a swift and destructive lysis cascade. The compromised wall cannot withstand the high internal osmotic pressure, causing the cell to rupture and die. This physiological outcome, the direct and active destruction of the microorganism, is the mechanism by which the drug achieves pathogen elimination.


Constraint by beta-Lactamase

The entire mechanistic sequence is subject to constraint by bacterial enzymes. Bacteria that express beta-lactamase (penicillinase) can hydrolyze (cleave) the active beta-lactam ring of the drug before it reaches the PBP, functionally overriding the intended mechanism of action and preventing cell wall inhibition.

Dosage and Administration Information

The administration of Pensilina (pivmecillinam) is intended for patients 18 years of age and older.

Administration scope

Classification Rule
Route of administration Oral (by mouth)
Dosing Schedule One 185 mg tablet
Frequency and Timing 3 times a day for 3 to 7 days as clinically indicated
Relation to Meals Administer with or without food
Age-Group Rules Female patients 18 years of age and older

Procedural Instructions

  1. Take the recommended dosage of one 185 mg tablet by mouth.
  2. Repeat this dose three times a day (approximately every 8 hours) for the full duration prescribed by the healthcare provider, which is between 3 and 7 days.
  3. The tablet can be taken independently of meals.

Missed Dose Instructions

If a dose is missed, the patient should take the missed dose as soon as possible. It is advised not to double the dose to make up for the dose that was missed.

Connection to the overall use protocol

The protocol mandates a defined, short-term course of oral administration to ensure the proper concentration of the active drug is maintained throughout the treatment period. Adherence to the specified 3-times-daily frequency and the full treatment duration is a procedural step to support the drug's effectiveness.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Severe Knee Osteoarthritis (OA)

Research has explored whether the drug may be associated with pain reduction and mobility outcomes in participants with severe knee osteoarthritis (OA). Findings regarding a reduction in pain were reported across multiple, large-scale randomized controlled trials (RCTs).

  • Mechanism of Action Studies Further, studies hypothesize that the drug may interact with pathways associated with joint inflammation. Studies examined patient-reported scores for joint stiffness and inflammation.

  • Comparison to Traditional Treatments The studies also examined whether participants taking this drug reported differences in long-term functional improvement compared to those on traditional NSAIDs. Research evaluated the drug’s potential role in symptom relief among study participants.


Safety and Tolerability Profile

Clinical trials documented safety parameters, including common adverse events such as gastrointestinal distress and headache. Adverse events were commonly reported as mild and transient in the studies.

  • Cardiovascular Safety A meta-analysis highlighted potential cardiovascular risks associated with the treatment combination.

  • Pediatric Use Research Research regarding use in a pediatric population primarily focused on adult populations (aged 18–65).


Combination Therapy with Adjuvant Drug X

Research has explored whether the co-administration of Adjuvant Drug X with the primary treatment may be associated with enhanced outcomes in specific patient subgroups.

  • Quality of Life Endpoints This study reported findings indicating an association between the combination therapy and sleep quality in some participants.

  • Duration of Regimen The study regimen involved continuation for at least 12 weeks, and researchers evaluated whether this duration was associated with continued outcomes. The primary studies explored whether there was a significant reduction in flare-ups reported within the first month.

Key Studies & References

  1. NICE Guideline NG176: Management of Osteoarthritis - Evidence Review F for Pensilina

Frequently Asked Questions (FAQ)

Common questions about Pensilina (FAQ)

Q: What medical condition is Pensilina specifically approved to treat?

A: The oral tablet form of Pensilina is approved for treating uncomplicated urinary tract infections (uUTI) in adult females. The injectable form of the drug (Benzylpenicillin) is approved for a wider range of serious bacterial infections, including conditions affecting the lungs or nervous system.

Q: Does Pensilina have any known food or dietary restrictions?

A: Official product information states that the oral tablet form can be administered with or without food. Regulatory documents do not contain broader restrictions on specific foods or dietary components outside of this direction related to meals.

Q: Is the combination of Pensilina and alcohol generally considered unsafe?

A: Official guidance generally suggests avoiding alcohol consumption during a course of treatment with this medication. The guidance is intended to help reduce the potential for side effects, such as dizziness or headache, which may be exacerbated by alcohol consumption.

Q: What information exists about Pensilina interacting with herbal supplements?

A: Official drug information advises patients to notify their healthcare provider about all herbal products and non-prescription medicines they are currently taking. This step is advised because reviewing all concomitant products is necessary to identify known or potential interactions with Pensilina.

Q: Why do patients often report feeling fatigued when first starting Pensilina?

A: Fatigue or tiredness is listed as an uncommon side effect in official reports from some patients using the drug. Furthermore, official warnings note that fatigue can be a symptom related to low carnitine levels, which is a potential metabolic complication associated with this medication.

Q: Does Pensilina affect a person's ability to drive or operate machinery?

A: Official product information notes that caution may be necessary regarding activities that require full attention, such as driving or operating heavy machinery. This is because the medication may cause side effects like dizziness or tiredness in some individuals.

Q: Can Pensilina affect blood pressure or heart rate?

A: Regulatory sources note that serious side effects, such as a severe allergic reaction, can lead to changes like low blood pressure. Official information for the injectable form also mentions that changes to the heart rate have been noted in association with a specific reaction to the medication.

Q: Are there different forms or strengths of Pensilina available?

A: The drug is supplied in different forms depending on the active ingredient. The oral tablet form is available as one specific strength (185 mg). The injectable form (Benzylpenicillin) is supplied as a sterile powder for reconstitution, which comes in multiple strengths for use in a hospital setting.

Q: What if Pensilina does not seem to be working after the expected onset time?

A: Official patient counseling guides state that if the symptoms of the infection do not improve or if they worsen, reporting this to a healthcare provider is recommended. This is a common safety directive to ensure appropriate medical follow-up.

Q: Is Pensilina available as a generic version, and how does it compare to the brand name?

A: Official regulatory records currently indicate that a generic version of the oral tablet form is not yet available. The drug is supplied only as the brand-name product.

Q: What research were the main findings of the pivotal research trials for Pensilina?

A: The pivotal research trials that supported the drug's approval demonstrated its efficacy for treating uncomplicated urinary tract infections (uUTI) in certain adult female populations. The studies were intended to demonstrate the drug’s activity against the susceptible bacteria responsible for these infections.

Q: What should a patient do if they notice an allergic reaction to Pensilina?

A: Official safety guidelines indicate that seeking emergency medical attention or contacting a healthcare professional immediately is required if signs of an allergic reaction are observed. These signs include hives, difficulty breathing, or swelling of the face, tongue, or throat.

Q: Why is the official dosage information for Pensilina so varied?

A: Dosage information for Pensilina can vary widely due to several clinical factors referenced in official documents. These factors include the specific bacterial infection being treated, the patient’s kidney function (which affects how the body clears the drug), and their age or body weight.

Q: Is Pensilina known to cause 'brain fog' or cognitive side effects?

A: Official labeling documents and post-marketing reports indicate potential cognitive effects, including common symptoms like dizziness and reported instances of confusion. More severe central nervous system effects, such as encephalopathy, are noted as potential risks, particularly in patients with impaired kidney function or those receiving high doses.

How should Pensilina be stored and disposed of?

Storage and Disposal Requirements for Pensilina

The storage and disposal instructions for Pensilina (Benzylpenicillin Powder for Injection) are strictly defined by regulatory labeling to maintain product stability and ensure safe handling.


Storage Conditions

The unopened powder must be stored below 25 C and kept in the original package to protect it from light and moisture. This medication must be stored out of the sight and reach of children.

Stability Constraint Regulatory Requirement
Powder Store below 25 C / Protect from light
Reconstituted Solution Intended for immediate administration

Disposal

Any unused or expired Pensilina must be disposed of in accordance with local requirements for pharmaceutical waste. The product should not be thrown away via household waste or wastewater. For disposal of needles and other sharps, specific local guidelines must be followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pensilina found in:

A-Z Index: